Pfizer reports Phase 3 success for Litfulo in vitiligo trials; Braveheart and Attovia target $275M and $182M IPOs

Pfizer announced that its experimental drug Litfulo achieved Phase 3 success in two separate studies targeting active and stable nonsegmental vitiligo, an autoimmune condition that causes loss of skin color.

Both trials met their primary endpoints, indicating the therapy’s potential effectiveness for patients with this form of vitiligo.

At the same time, biotech firms Braveheart and Attovia disclosed plans for initial public offerings, aiming to raise approximately $275 million and $182 million respectively.

The positive trial outcomes and upcoming IPOs could influence market expectations for dermatology treatments and biotech financing.